According to incomplete statistics from Innovation Radar, last week (June 9 to June 15), the global pharmaceuticals and healthcare sector...A total of 28 financing events were disclosed, with a total amount of nearly 7.5 billion US dollars., coveringAdeno-Associated Virus (AAV)Gene therapy, radiopharmaceuticals, small-molecule anticancer drugs, peptide vaccines, and other fields.

Last week, the company with the highest single financing was a small molecule drug research and development company.Antares Therapeutics Secures $177 Million in Series A FundingAntares Therapeutics was spun off from Scorpion Therapeutics.Focus on the Development of “Undruggable” Targets, including areas that are difficult for traditional small molecules to intervene in, such as transcription factors. The plan is to advance a precision oncology project by integrating computational chemistry with experimental biology techniques, with the first candidate drug expected to enter clinical trials in 2026. Additionally, Antares announced the transfer of global rights to two EGFR inhibitors (for non-small cell lung cancer indications) to Pierre Fabre Laboratories, with potential future milestone payments and tiered royalties.

There are also advances in other small molecule drug fields. For example,Mosanna Therapeutics Completes $80 Million Series A Financing, advancing the Phase 2 clinical trial of the nighttime nasal spray MOS118 for the treatment of obstructive sleep apnea (OSA).

Last week, the gene therapy sector showed relatively active financing.European Company SpliceBio Completes $135 Million Series B Financing Round with Investments from Sanofi, Roche, Novartis, and Other Institutions, will advance the clinical development of core pipeline SB-007, a therapy targetingABCA4Stargardt disease, a rare ocular condition caused by genetic mutations, currently has no approved therapies available globally. SB-007 is a dual AAV gene therapy that delivers the full-length protein through protein splicing technology.ABCA4Protein gene, covering all mutation-type patients.

Except for SpliceBio,Innovecbio Secures Tens of Millions in A+ Round FundingFocusing on the development of AAV delivery technology platforms to advance the clinical translation of gene therapies for ophthalmic, muscular, and neurodegenerative diseases.

In the field of nuclear medicine,AB-RayBio Raises Tens of Millions in Angel Round Financing, focusing on the development of nuclear medicines using α and β emitters, currently has 8 ongoing R&D pipelines.

Readers, please star ⭐Chuangjian News, and you will receive the push notification at the first time.

Disclaimer: This article is for the purpose of information exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with friends circle individually. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"InnoVec Biotherapeutics Inc."Contact us through the WeChat Official Account comments.

More Data Content Recommendations

Click "InSee", Share Chuangjian Hui Health New Trends